These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8110237)

  • 1. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
    Florkowski CM
    Med J Aust; 1993 Nov; 159(10):711-2. PubMed ID: 8110237
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
    Hotta N; Sakamoto N
    Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy.
    Gill JS; Williams G; Ghatei MA; Hetreed AH; Mather HM; Bloom SR
    Diabete Metab; 1990; 16(4):296-302. PubMed ID: 2125013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
    Yue DK; Brooks B
    Med J Aust; 1993 Jul; 159(2):76-8. PubMed ID: 8336605
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
    Wright M; Hill S; Slaney MA
    Med J Aust; 1994 Jan; 160(1):45. PubMed ID: 8123141
    [No Abstract]   [Full Text] [Related]  

  • 6. Recent clinical experience with aldose reductase inhibitors.
    Krans HM
    Diabet Med; 1993; 10 Suppl 2():44S-48S. PubMed ID: 8334842
    [No Abstract]   [Full Text] [Related]  

  • 7. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].
    Christensen JE; Larsen AB; Gregersen G
    Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975
    [No Abstract]   [Full Text] [Related]  

  • 8. New approaches for treatment in diabetes: aldose reductase inhibitors.
    Hotta N
    Biomed Pharmacother; 1995; 49(5):232-43. PubMed ID: 7579002
    [No Abstract]   [Full Text] [Related]  

  • 9. Aldose reductase inhibitors--hope or hype.
    Raskin P
    J Diabetes Complications; 1992; 6(2):69. PubMed ID: 1611141
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor.
    Faes TJ; Yff GA; DeWeerdt O; Lanting P; Heimans JJ; Bertelsmann FW
    J Neurol; 1993; 240(3):156-60. PubMed ID: 8482988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
    Baba M; Kimura K; Suda T; Yagihashi S;
    J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
    [No Abstract]   [Full Text] [Related]  

  • 12. [Diabetes mellitus and its complications in Japan. Polyol pathway and diabetic neuropathy: selective preventive effect of aldose reductase inhibitor on the experimental diabetic neuropathy].
    Kamijo M; Yagihashi S
    Nihon Naika Gakkai Zasshi; 1991 Sep; 80(9):1457-9. PubMed ID: 1837043
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
    Greene DA
    J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.
    Valensi P; Le Devehat C; Richard JL; Farez C; Khodabandehlou T; Rosenbloom RA; LeFante C
    J Diabetes Complications; 2005; 19(5):247-53. PubMed ID: 16112498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration.
    Johnson BF; Nesto RW; Pfeifer MA; Slater WR; Vinik AI; Chyun DA; Law G; Wackers FJ; Young LH
    Diabetes Care; 2004 Feb; 27(2):448-54. PubMed ID: 14747227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug therapy of diabetic neuropathy.
    Brooks PJ; Francisco GE
    Clin Podiatr Med Surg; 1992 Apr; 9(2):257-74. PubMed ID: 1586903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.
    Masson EA; Boulton AJ
    Drugs; 1990 Feb; 39(2):190-202. PubMed ID: 2109678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment with an aldose reductase inhibitor in peripheral neuropathy in elderly diabetic patients].
    Terranova R; Luca S
    Minerva Med; 1993 Sep; 84(9):461-6. PubMed ID: 8247317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
    Shimoshige Y; Ikuma K; Yamamoto T; Takakura S; Kawamura I; Seki J; Mutoh S; Goto T
    Metabolism; 2000 Nov; 49(11):1395-9. PubMed ID: 11092500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.